On October 30, 2018 NewLink Genetics Corporation (NASDAQ:NLNK), a clinical stage biopharmaceutical company focused on developing novel immuno-oncology therapeutic candidates, reported it will present at the Stifel 2018 Healthcare Conference (Press release, NewLink Genetics, OCT 30, 2018, View Source [SID1234530682]). The conference is being held on November 13 – 14 at the Lotte New York Palace Hotel in New York City, New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NewLink’s management will participate in an analyst-led fireside chat Tuesday, November 13, 2018 from 11:45 AM – 12:25 PM ET and will be available for one-on-one meetings with investors who are registered to attend the conference.

A live webcast of the conference presentation will be available on the Company’s website at www.newlinkgenetics.com in the "Investors & Media" section under "Events & Presentations".